<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512783</url>
  </required_header>
  <id_info>
    <org_study_id>1302-019</org_study_id>
    <nct_id>NCT02512783</nct_id>
  </id_info>
  <brief_title>Decreasing Propofol Injection Pain by Pre-Treatment With Lidocaine in Pediatric Procedural Sedation</brief_title>
  <official_title>Decreasing Propofol Injection Pain by Pre-Treatment With Lidocaine in Pediatric Procedural Sedation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospitals and Clinics of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospitals and Clinics of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind, randomized, controlled study. The sedationist performing the sedation
      procedure will inject the appropriate amount of either a 1% Lidocaine solution or a placebo
      before the administration of Propofol. A research staff will observe the patient
      simultaneously with the induction of Propofol to determine the patient's pain level, as
      measured by the Face, Legs, Activity, Cry, Consolability (FLACC) scale. The purpose of this
      study is to determine the efficacy of premedication with 1% Lidocaine in decreasing the
      burning sensation caused by intravenous Propofol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Propofol is a short-acting, intravenously administered anesthetic. It has become a popular
      choice for procedural sedation in both children and adults. Despite its many advantages,
      Propofol is associated with a burning sensation during injection. Propofol pain begins within
      the first few seconds after administration and often lasts approximately 10-20 seconds until
      the patient is asleep. Lidocaine is often used in an attempt to reduce Propofol injection
      pain, but neither its delivery mode nor concentration has been standardized.

      The purpose of this study is to determine the efficacy of premedication with 1% Lidocaine in
      decreasing the burning sensation caused by intravenous Propofol.

      This is a double blind, randomized, controlled study. The sedationist performing the sedation
      procedure will inject the appropriate amount of either a 1% Lidocaine solution or a placebo
      before the administration of Propofol. A research staff will observe the patient
      simultaneously with the induction of Propofol to determine the patient's pain level, as
      measured by the FLACC scale.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis indicated treatment was effective and statistically significant
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in FLACC (Face, Legs, Activity, Cry, Consolability) Score</measure>
    <time_frame>1 minute before propofol induction compared to 1 minute following propofol induction</time_frame>
    <description>The FLACC scale measures pain in children aged 2m-7y. The scale ranges from 0-10 with 0 being no pain. The total score out of 10 is based on 5 pieces of criteria, and each criteria is scored as either 0, 1, or 2. Scores on individual criteria are summed up to give a total score. Higher values represent a worse outcome of more pain. FLACC scores will be compared pre- and post-propofol induction to assess the change in FLACC score for each arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parental Assessment of Child's Pain on a Visual Analog Scale</measure>
    <time_frame>Immediately following propofol injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation</description>
    <arm_group_label>Lidocaine</arm_group_label>
    <other_name>Xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Intravenous administration of propofol according to standard care to sedate patient.</description>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_label>Normal Saline</arm_group_label>
    <other_name>Diprivan</other_name>
    <other_name>Fresenius Propoven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 2 months to 17 years

          -  patient already scheduled for procedural sedation with propofol

          -  sedation procedure to be performed by a sedationist from Children's Respiratory and
             Critical Care Specialists

        Exclusion Criteria:

          -  patients who are not receiving deep sedation with propofol

          -  patients with allergy or other contraindication to lidocaine administration

          -  patients with central venous catheters as propofol does not burn when given centrally

          -  patients being premedicated with an analgesic other than nitrous oxide or 1% lidocaine

          -  patients weighing less than 5 kg to prevent any risk of inadvertent lidocaine
             overdose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didima Mon-Sprehe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospitals and Clinics of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2013</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <results_first_submitted>February 22, 2016</results_first_submitted>
  <results_first_submitted_qc>May 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2016</results_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Propofol</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Intravenous propofol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine</title>
          <description>Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
Lidocaine: Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
Propofol: Intravenous administration of propofol according to standard care to sedate patient.</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline</title>
          <description>Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
Normal Saline: Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
Propofol: Intravenous administration of propofol according to standard care to sedate patient.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine</title>
          <description>Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
Lidocaine: Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
Propofol: Intravenous administration of propofol according to standard care to sedate patient.</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline</title>
          <description>Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
Normal Saline: Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
Propofol: Intravenous administration of propofol according to standard care to sedate patient.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="96"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="171"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in FLACC (Face, Legs, Activity, Cry, Consolability) Score</title>
        <description>The FLACC scale measures pain in children aged 2m-7y. The scale ranges from 0-10 with 0 being no pain. The total score out of 10 is based on 5 pieces of criteria, and each criteria is scored as either 0, 1, or 2. Scores on individual criteria are summed up to give a total score. Higher values represent a worse outcome of more pain. FLACC scores will be compared pre- and post-propofol induction to assess the change in FLACC score for each arm.</description>
        <time_frame>1 minute before propofol induction compared to 1 minute following propofol induction</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
Lidocaine: Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
Propofol: Intravenous administration of propofol according to standard care to sedate patient.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
Normal Saline: Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
Propofol: Intravenous administration of propofol according to standard care to sedate patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FLACC (Face, Legs, Activity, Cry, Consolability) Score</title>
          <description>The FLACC scale measures pain in children aged 2m-7y. The scale ranges from 0-10 with 0 being no pain. The total score out of 10 is based on 5 pieces of criteria, and each criteria is scored as either 0, 1, or 2. Scores on individual criteria are summed up to give a total score. Higher values represent a worse outcome of more pain. FLACC scores will be compared pre- and post-propofol induction to assess the change in FLACC score for each arm.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".82" spread="2.357"/>
                    <measurement group_id="O2" value="2.43" spread="3.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parental Assessment of Child's Pain on a Visual Analog Scale</title>
        <time_frame>Immediately following propofol injection</time_frame>
        <population>This data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
Lidocaine: Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
Propofol: Intravenous administration of propofol according to standard care to sedate patient.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
Normal Saline: Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
Propofol: Intravenous administration of propofol according to standard care to sedate patient.</description>
          </group>
        </group_list>
        <measure>
          <title>Parental Assessment of Child's Pain on a Visual Analog Scale</title>
          <population>This data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine</title>
          <description>Administration of 1ml of pre-treatment 1% lidocaine immediately prior to propofol induction.
Lidocaine: Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
Propofol: Intravenous administration of propofol according to standard care to sedate patient.</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>Administration of 1ml of pre-treatment normal saline immediately prior to propofol induction.
Normal Saline: Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
Propofol: Intravenous administration of propofol according to standard care to sedate patient.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela Doucette</name_or_title>
      <organization>Children's Hospitals and Clinics of Minnesota</organization>
      <phone>6128137144</phone>
      <email>angela.doucette@childrensmn.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

